Résumé
Background: The immunosuppressed population continues to be affected by the widespread COVID-19 pandemic, caused by the SARSCoV- 2. Patients with hematological malignancies are prone to get infected by this pathogen because of their immunosuppressive treatments and/or underlying comorbidities. Therefore, neutralizing monoclonal antibodies such as Sotrovimab have been used as treatment.Aim: The purpose of this study is to compare the outcomes of patients having received Sotrovimab to those of a control group and to assess the post-covid hematological status of both groups regarding the treatments they had received. Methods: A retrospective study was conducted in the hematology department of CHU UCL Namur site Godinne on 87 positive COVID-19 patients. Among them, 43 patients received Sotrovimab and 44 were part of the control group. Clinical and demographic data were retrieved from patient medical files, and data were analyzed using R commander (version 4.1.1). Hematological malignancies were classified as Leukemia, Lymphoma, Myeloma, and others including Melodysplastic syndromes, Myelofibrosis, Beta-Thalassemia major and Polycythemia. Besides, Chi square and Fisher tests were applied to evaluate the statistical significance. Analysis: Out of 87 patients, the Sotrovimab group included 26 men (60.5 %) and 17 females 2 (39.5 %), and the control group included 27 men (61.4 %) men and 17 females (38.6 %). A decrease in the features of severe Covid-19 were observed in the Sotrovimab group compared to the control one: (i) oxygen therapy (n = 9 ; 20.9 % versus n = 29 ; 65.9 % ; p-value Conclusion: This study showed that the risk of severe COVID-19 outcomes is significantly decreased with sotrovimab therapy. However, alternatives to Sotrovimab are needed to fight against new variants of Omicron.
| la date de réponse | 17 janv. 2023 |
|---|---|
| langue originale | Anglais |
| L'institution diplômante |
|
| Superviseur | Marc Andre (Promoteur) |